Browse

Phase II clinical trial of induction chemotherapy with fixed dose rate gemcitabine and cisplatin followed by concurrent chemoradiotherapy with capecitabine for locally advanced pancreatic cancer

Cited 14 time in Web of Science Cited 16 time in Scopus
Authors
Kim, Jae-Sung; Lim, Joo Han; Kim, Jee Hyun; Im, Seock-Ah; Chie, Eui Kyu; Hwang, Jin-Hyeok; Kim, Tae-You; Bang, Yung-Jue; Ha, Sung Whan; Yoon, Yong Bum
Issue Date
2012-09
Citation
Cancer Chemotherapy and Pharmacology, Vol.70 No.3, pp.381-389
Keywords
Induction chemotherapyPancreatic cancerChemoradiotherapyGemcitabine
Abstract
5-FU-based concurrent chemoradiotherapy (CRT) has been the mainstay of treatment for locally advanced pancreatic cancer (LAPC) for the past decades, but the prognosis remains dismal. Patients with pathologically confirmed LAPC of the pancreas, an ECOG PS of 0-2 and no prior chemo- or radiotherapy were eligible. The treatment consisted of induction (IND) chemotherapy with a fixed dose rate gemcitabine 1,000 mg/mA(2) on days 1 and 8 and CDDP 60 mg/mA(2) on day 1 every 3 weeks for 3 cycles. Subsequently, the patients without progression received CRT of 55.8 Gy/31 fractions with capecitabine 650 mg/mA(2) twice daily. Gemcitabine was given for 3 cycles after CRT. The primary endpoint was time to progression. Thirty-seven patients with LAPC were enrolled. Median age was 55 years, there were 20 males and 17 females, and ECOG PS was 0 in 6 and 1 in 31. Three patients (9.7 %) achieved partial responses after IND chemotherapy. Twenty-five patients received CRT with a mean radiation dose of 54.0 Gy, with one additional patient achieving a partial response. The median time to progression was 7.2 months (95 % CI, 4.4-10), and the median overall survival was 16.8 months (95 % CI, 12.9-20.7). The grade 3/4 toxicities included neutropenia (29 %/6.5 %), thrombocytopenia (3.2 %/0 %) and anemia (9.7 %/0 %) during the IND phase and grade 3 neutropenia and diarrhea occurring in one and two patients during CRT phase. IND chemotherapy with gemcitabine and cisplatin followed by CRT with capecitabine and maintenance gemcitabine was well tolerated and exhibited promising efficacy for the treatment of LAPC.
ISSN
0344-5704
URI
https://hdl.handle.net/10371/173020
DOI
https://doi.org/10.1007/s00280-012-1918-7
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse